MS News from the Accelerated Cure Project:
1. Extended release form of Baclofen
Published Story by art http://msnews.acceleratedcure.org/node/3355
IPX056 has met [269] its clinical endpoints in Impax Laboratories’ Phase III study of spasticity in multiple sclerosis patients.
The drug is an extended-release formulation of baclofen, a common treatment for spasticity, which has the potential to offer improved control of symptoms and dosing convenience, according to Impax.
[269] http://fdanews.com/newsletter/article?issueId=11856&articleId=109406
-------------------------------------------
2. ATL1102 now ATL/TV1102
Published Story by art http://msnews.acceleratedcure.org/node/3356
ATL1102 is a drug, similar to Tysabri, developed by Antisense Therapeutics. On 30 June 2008 Teva and Antisense Therapeutics announced [270] the results of the Phase IIa MS trial and reported that ATL/TV1102 (ne
ATL1102) significantly reduced disease activity in patients with RRMS and that the Phase IIa study met its primary endpoint showing a significant reduction by 54.4% in cumulative number of new active lesions in patients taking ATL/TV1102 for 8 weeks, compared to placebo, as measured by magnetic resonance images (MRI). ATL/TV1102 demonstrated an increasing effect with time on the reduction of new active lesions over 12 weeks - one month after the completion of dosing.
[270] http://newsstore.smh.com.au/apps/previewDocument.ac?docID=GCA00869021ANP
|
1. Extended release form of Baclofen
Published Story by art http://msnews.acceleratedcure.org/node/3355
IPX056 has met [269] its clinical endpoints in Impax Laboratories’ Phase III study of spasticity in multiple sclerosis patients.
The drug is an extended-release formulation of baclofen, a common treatment for spasticity, which has the potential to offer improved control of symptoms and dosing convenience, according to Impax.
[269] http://fdanews.com/newsletter/article?issueId=11856&articleId=109406
-------------------------------------------
2. ATL1102 now ATL/TV1102
Published Story by art http://msnews.acceleratedcure.org/node/3356
ATL1102 is a drug, similar to Tysabri, developed by Antisense Therapeutics. On 30 June 2008 Teva and Antisense Therapeutics announced [270] the results of the Phase IIa MS trial and reported that ATL/TV1102 (ne
ATL1102) significantly reduced disease activity in patients with RRMS and that the Phase IIa study met its primary endpoint showing a significant reduction by 54.4% in cumulative number of new active lesions in patients taking ATL/TV1102 for 8 weeks, compared to placebo, as measured by magnetic resonance images (MRI). ATL/TV1102 demonstrated an increasing effect with time on the reduction of new active lesions over 12 weeks - one month after the completion of dosing.
[270] http://newsstore.smh.com.au/apps/previewDocument.ac?docID=GCA00869021ANP